Enzyme Linked Immunosorbent Assay (ELISA) News and Research

RSS
Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

Study links COVID-19 inflammatory manifestations in brain lysates to Alzheimer’s Disease markers

Study links COVID-19 inflammatory manifestations in brain lysates to Alzheimer’s Disease markers

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Memory B cells found to potently neutralize SARS-CoV-2 Omicron variant

Memory B cells found to potently neutralize SARS-CoV-2 Omicron variant

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Researchers develop a single-use sensor strip to detect cerebrospinal fluid leaks

Researchers develop a single-use sensor strip to detect cerebrospinal fluid leaks

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.